Pharmaceuticals

Radiopharmaceuticals Market Outlook: Growth and Forecast Highlights 2030

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the radiopharmaceuticals market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Radiopharmaceuticals Market between 2026 and 2030?

In recent years, the radiopharmaceuticals market size has expanded rapidly. It is anticipated to increase from $7.3 billion in 2025 to $8.25 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. The growth observed in prior periods can be attributed to the adoption of nuclear imaging technologies, an uptick in cancer diagnosis rates, the accessibility of radioisotopes, the expansion of hospital-based nuclear medicine facilities, and regulatory clearances for diagnostic agents.

The radiopharmaceuticals market is expected to experience substantial growth in the coming years, with its size projected to reach $13.68 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. This anticipated growth during the forecast period can be attributed to several factors, including the expansion of precision oncology, a rising demand for targeted radiotherapies, the proliferation of diagnostic imaging centers, increased investments in cyclotron infrastructure, and technological advancements in isotope production. Key trends in the forecast period will involve the increasing application of radiopharmaceuticals in oncology, the growth of theranostics uses, the broader expansion of PET and SPECT imaging, accelerated development of targeted radiotherapies, and improvements in nuclear medicine infrastructure.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3471&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Radiopharmaceuticals Market?

The growing occurrence of cancer and cardiovascular ailments is anticipated to fuel the need for the radiopharmaceuticals market. These radiopharmaceuticals are proving to be a secure and efficient treatment alternative compared to traditional medications. Thanks to advantages like targeted therapy, radiopharmaceuticals offer radiologists a significant edge in managing cancer and cardiovascular conditions. Cancer stands as the second leading global cause of mortality, responsible for approximately 1 in 6 deaths across the world. For example, data from April 2024, provided by the International Agency for Research on Cancer (IARC), a specialized agency based in France, indicates that in 2022, the world saw almost 20 million new cancer diagnoses and 9.7 million fatalities linked to cancer. Projections suggest that by 2040, these figures will rise to an annual 29.9 million new cases and 15.3 million deaths. Consequently, the escalating incidence of cancer and cardiovascular diseases is set to boost the demand for radiopharmaceuticals used in their treatment.

What Segments Are Included Within The Radiopharmaceuticals Market?

The radiopharmaceuticals market covered in this report is segmented –

1) By Type: Diagnostic, Therapeutic

2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications

3) By End User: Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes

Subsegments:

1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals, Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals

2) By Therapeutic: Alpha Emitters, Beta Emitters, Brachytherapy

What Trends Are Expected To Impact The Competitive Landscape Of The Radiopharmaceuticals Market?

Major companies operating in the radiopharmaceuticals market are increasingly forming strategic partnerships to accelerate innovation and expand access to advanced diagnostic and therapeutic solutions. These collaborations focus on enhancing radiopharmaceutical development, strengthening regional production capabilities, and supporting the growing demand for precision imaging and targeted therapies. For instance, in June 2023, the University of Pittsburgh Medical Center (UPMC), a US-based hospital system, partnered with PharmaLogic Holdings Corporation to co-develop and manufacture new radiopharmaceuticals at a Pittsburgh facility. The partnership aims to expand patient and clinician access to cutting-edge diagnostic and therapeutic agents that are not currently available in nearby regions. Under the non-exclusive agreement, UPMC and PharmaLogic will translate experimental radiopharmaceuticals into clinically useful medications, supporting broader commercialization and accelerating the adoption of novel nuclear medicine treatments.

Who Are The Major Companies Operating In The Radiopharmaceuticals Market?

Major companies operating in the radiopharmaceuticals market are Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, ÚJV Rež, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacýbaþý-Monrol Nuclear Products, NTP Radioisotopes.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Radiopharmaceuticals Market?

North America was the largest region in the global radiopharmaceuticals market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Radiopharmaceuticals Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3471&type=smp

Browse Through More Reports Similar to the Global Radiopharmaceuticals Market 2026, By The Business Research Company

Radiotherapy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/radiotherapy-devices-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Diagnostic Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795